Detection of IL-17 and IL-23 in plasma samples of children with autism

Amanda Enstrom, Charity Onore, Irva Hertz-Picciotto, Robin L Hansen, Lisa Croen, Judith A Van de Water, Paul Ashwood

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Interleukin-23 (IL-23) is a survival factor for a newly described population of T lymphocytes, namely Th-17 cells, that secrete IL-17, tumor necrosis factor- alpha (TNFα) and IL-6. It has been shown that Th-17 cells are a pathogenic T cell subset involved in autoimmune and chronic inflammatory diseases. Based on the increasing evidence of immune dysfunction in autism, including possible autoimmune and inflammatory processes, we hypothesized that Th-17 cells, a T cell lineage that has not been previously examined in this disorder, may be altered in autism. To assess the potential role, if any, of Th-17 cells in autism, we analyzed plasma samples obtained from children ranging in age from 2-5 years with a diagnosis of autism and age-matched typically developing controls for the presence of IL-17 and IL-23 cytokines. Plasma samples from 40 children with autism including 20 children with a regressive form of autism, 20 with early onset and no regression and 20 typically developing age-matched control children were analyzed for IL-17 and IL-23, under the hypothesis that altered number and function of Th-17 cells would directly correlate with altered levels of IL-17 and IL-23 in the plasma. In this study, we were able to demonstrate that IL-23 cytokine levels were significantly different in children with autism compared with age-matched controls, a finding primarily driven by children with early onset autism. In contrast, there were no statistical differences in IL-17 levels autism compared with age-matched typically developing controls. This is the first study to report altered IL-23 production in autism. The decreased plasma IL-23 production observed in children with autism warrants further research as to its affect on the generation and survival of Th-17 cells, a subset important in neuroinflammatory conditions that may include autism.

Original languageEnglish (US)
Pages (from-to)114-120
Number of pages7
JournalAmerican Journal of Biochemistry and Biotechnology
Volume4
Issue number2
StatePublished - 2008

Fingerprint

Interleukin-23
Interleukin-17
Autistic Disorder
Plasmas
T-cells
Cytokines
Interleukin-6
T-Lymphocytes
Tumor Necrosis Factor-alpha
T-Lymphocyte Subsets
Cell Lineage
Chronic Disease

Keywords

  • Autism
  • IL-23
  • Inflammation
  • Neurodevelopment
  • Th-17 cells

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology

Cite this

Detection of IL-17 and IL-23 in plasma samples of children with autism. / Enstrom, Amanda; Onore, Charity; Hertz-Picciotto, Irva; Hansen, Robin L; Croen, Lisa; Van de Water, Judith A; Ashwood, Paul.

In: American Journal of Biochemistry and Biotechnology, Vol. 4, No. 2, 2008, p. 114-120.

Research output: Contribution to journalArticle

@article{99d91e7f07664de3940efd9384a84483,
title = "Detection of IL-17 and IL-23 in plasma samples of children with autism",
abstract = "Interleukin-23 (IL-23) is a survival factor for a newly described population of T lymphocytes, namely Th-17 cells, that secrete IL-17, tumor necrosis factor- alpha (TNFα) and IL-6. It has been shown that Th-17 cells are a pathogenic T cell subset involved in autoimmune and chronic inflammatory diseases. Based on the increasing evidence of immune dysfunction in autism, including possible autoimmune and inflammatory processes, we hypothesized that Th-17 cells, a T cell lineage that has not been previously examined in this disorder, may be altered in autism. To assess the potential role, if any, of Th-17 cells in autism, we analyzed plasma samples obtained from children ranging in age from 2-5 years with a diagnosis of autism and age-matched typically developing controls for the presence of IL-17 and IL-23 cytokines. Plasma samples from 40 children with autism including 20 children with a regressive form of autism, 20 with early onset and no regression and 20 typically developing age-matched control children were analyzed for IL-17 and IL-23, under the hypothesis that altered number and function of Th-17 cells would directly correlate with altered levels of IL-17 and IL-23 in the plasma. In this study, we were able to demonstrate that IL-23 cytokine levels were significantly different in children with autism compared with age-matched controls, a finding primarily driven by children with early onset autism. In contrast, there were no statistical differences in IL-17 levels autism compared with age-matched typically developing controls. This is the first study to report altered IL-23 production in autism. The decreased plasma IL-23 production observed in children with autism warrants further research as to its affect on the generation and survival of Th-17 cells, a subset important in neuroinflammatory conditions that may include autism.",
keywords = "Autism, IL-23, Inflammation, Neurodevelopment, Th-17 cells",
author = "Amanda Enstrom and Charity Onore and Irva Hertz-Picciotto and Hansen, {Robin L} and Lisa Croen and {Van de Water}, {Judith A} and Paul Ashwood",
year = "2008",
language = "English (US)",
volume = "4",
pages = "114--120",
journal = "American Journal of Biochemistry and Biotechnology",
issn = "1553-3468",
publisher = "Science Publications",
number = "2",

}

TY - JOUR

T1 - Detection of IL-17 and IL-23 in plasma samples of children with autism

AU - Enstrom, Amanda

AU - Onore, Charity

AU - Hertz-Picciotto, Irva

AU - Hansen, Robin L

AU - Croen, Lisa

AU - Van de Water, Judith A

AU - Ashwood, Paul

PY - 2008

Y1 - 2008

N2 - Interleukin-23 (IL-23) is a survival factor for a newly described population of T lymphocytes, namely Th-17 cells, that secrete IL-17, tumor necrosis factor- alpha (TNFα) and IL-6. It has been shown that Th-17 cells are a pathogenic T cell subset involved in autoimmune and chronic inflammatory diseases. Based on the increasing evidence of immune dysfunction in autism, including possible autoimmune and inflammatory processes, we hypothesized that Th-17 cells, a T cell lineage that has not been previously examined in this disorder, may be altered in autism. To assess the potential role, if any, of Th-17 cells in autism, we analyzed plasma samples obtained from children ranging in age from 2-5 years with a diagnosis of autism and age-matched typically developing controls for the presence of IL-17 and IL-23 cytokines. Plasma samples from 40 children with autism including 20 children with a regressive form of autism, 20 with early onset and no regression and 20 typically developing age-matched control children were analyzed for IL-17 and IL-23, under the hypothesis that altered number and function of Th-17 cells would directly correlate with altered levels of IL-17 and IL-23 in the plasma. In this study, we were able to demonstrate that IL-23 cytokine levels were significantly different in children with autism compared with age-matched controls, a finding primarily driven by children with early onset autism. In contrast, there were no statistical differences in IL-17 levels autism compared with age-matched typically developing controls. This is the first study to report altered IL-23 production in autism. The decreased plasma IL-23 production observed in children with autism warrants further research as to its affect on the generation and survival of Th-17 cells, a subset important in neuroinflammatory conditions that may include autism.

AB - Interleukin-23 (IL-23) is a survival factor for a newly described population of T lymphocytes, namely Th-17 cells, that secrete IL-17, tumor necrosis factor- alpha (TNFα) and IL-6. It has been shown that Th-17 cells are a pathogenic T cell subset involved in autoimmune and chronic inflammatory diseases. Based on the increasing evidence of immune dysfunction in autism, including possible autoimmune and inflammatory processes, we hypothesized that Th-17 cells, a T cell lineage that has not been previously examined in this disorder, may be altered in autism. To assess the potential role, if any, of Th-17 cells in autism, we analyzed plasma samples obtained from children ranging in age from 2-5 years with a diagnosis of autism and age-matched typically developing controls for the presence of IL-17 and IL-23 cytokines. Plasma samples from 40 children with autism including 20 children with a regressive form of autism, 20 with early onset and no regression and 20 typically developing age-matched control children were analyzed for IL-17 and IL-23, under the hypothesis that altered number and function of Th-17 cells would directly correlate with altered levels of IL-17 and IL-23 in the plasma. In this study, we were able to demonstrate that IL-23 cytokine levels were significantly different in children with autism compared with age-matched controls, a finding primarily driven by children with early onset autism. In contrast, there were no statistical differences in IL-17 levels autism compared with age-matched typically developing controls. This is the first study to report altered IL-23 production in autism. The decreased plasma IL-23 production observed in children with autism warrants further research as to its affect on the generation and survival of Th-17 cells, a subset important in neuroinflammatory conditions that may include autism.

KW - Autism

KW - IL-23

KW - Inflammation

KW - Neurodevelopment

KW - Th-17 cells

UR - http://www.scopus.com/inward/record.url?scp=42449120078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449120078&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:42449120078

VL - 4

SP - 114

EP - 120

JO - American Journal of Biochemistry and Biotechnology

JF - American Journal of Biochemistry and Biotechnology

SN - 1553-3468

IS - 2

ER -